Key Takeaways
- Contrave (naltrexone-bupropion) is NOT a DEA-controlled substance and has no federal scheduling classification
- Neither naltrexone nor bupropion appears on the DEA controlled substances list dated August 27, 2026, and the Contrave label (revised 11/2025) reports no evidence of euphoric drug intoxication, physical dependence, diversion or abuse in outpatient studies of up to 56 weeks, while noting that a single 400 mg dose of bupropion produced mild amphetamine-like activity in drug-experienced subjects
- Contrave prescriptions do not require DEA numbers, state-specific controlled substance monitoring, or triplicate forms
- The confusion stems from comparing Contrave to older weight-loss drugs like phentermine (Schedule IV) and the historical misclassification of bupropion's mechanism
The short answer
No. As of September 5, 2026, Contrave is not a controlled substance. Neither Contrave, naltrexone nor bupropion appears on the DEA's alphabetical list of controlled substances dated August 27, 2026, and the FDA-approved label (revised 11/2025) has no Controlled Substance subsection, which scheduled drugs carry. The label's abuse section says outpatient studies of up to 56 weeks showed no evidence of euphoric drug intoxication, physical dependence, diversion or abuse. Prescribers do not need a DEA registration to write Contrave, and federal law does not require pharmacies to report its dispensing to state prescription drug monitoring programs.
Table of contents
- The DEA scheduling system: what controlled substance classification actually means
- Contrave's components and their individual classifications
- Why bupropion is not controlled despite being a stimulant-adjacent antidepressant
- The clinical evidence on abuse potential for naltrexone-bupropion
- What most articles get wrong about Contrave and controlled substances
- How Contrave prescribing differs from phentermine and other scheduled weight-loss drugs
- State-level variations: the three states with special bupropion rules
- The prescribing advantage: why non-controlled status matters for patients
- Comparison to GLP-1 medications: scheduling status across weight-loss drug classes
- When controlled substance status actually affects treatment decisions
- The primary-source answer: DEA list and label
- Scheduled weight-loss drugs Contrave is not
- What Contrave costs in 2026
- How much weight people lose on Contrave
- Not controlled does not mean low-risk
- FAQ
- Footer disclaimers
The DEA scheduling system: what controlled substance classification actually means
The Drug Enforcement Administration (DEA) classifies medications into five schedules based on abuse potential, accepted medical use, and safety profile. The system matters because it determines prescribing restrictions, pharmacy storage requirements, and whether dispensing gets reported to state monitoring programs.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Schedule I: No accepted medical use, high abuse potential (heroin, LSD, marijuana at federal level). Not prescribable.
Schedule II: High abuse potential but accepted medical use (oxycodone, amphetamine, fentanyl). Requires written prescription in most states, no refills, mandatory PDMP reporting.
Schedule III: Moderate abuse potential (codeine combinations, testosterone, ketamine). Written or electronic prescription, up to 5 refills in 6 months, PDMP reporting.
Schedule IV: Lower abuse potential (alprazolam, zolpidem, phentermine). Same prescribing rules as Schedule III but fewer pharmacy storage restrictions.
Schedule V: Lowest abuse potential among controlled substances (cough preparations with small amounts of codeine). Some available without prescription in certain states.
Unscheduled: No DEA classification. Normal prescription rules apply. No special storage, no PDMP reporting, no DEA number required. This is where Contrave sits.
The classification system is based on the Controlled Substances Act of 1970 and gets updated through a formal rulemaking process. The DEA reviews abuse potential data from clinical trials, post-market surveillance, emergency department visits, and law enforcement reports. A drug can be scheduled years after approval if abuse patterns emerge (tramadol was unscheduled until 2014, when it became Schedule IV).
Contrave has been on the market since 2014. No scheduling action has been proposed or initiated, and the DEA's alphabetical list of controlled substances dated August 27, 2026 contains no entry for Contrave, bupropion or naltrexone. The manufacturer today is Currax Pharmaceuticals.
Contrave's components and their individual classifications
Contrave contains two active ingredients in fixed-dose combination:
Naltrexone 8 mg (extended-release): An opioid receptor antagonist. Blocks mu, kappa, and delta opioid receptors. FDA-approved since 1984 for alcohol use disorder (50 mg daily dose) and opioid use disorder (as part of medication-assisted treatment). Naltrexone has ZERO abuse potential because it produces no euphoria, no physical dependence, and actively blocks the effects of opioids. It is the pharmacological opposite of an abusable substance. DEA classification: unscheduled.
Bupropion 90 mg (extended-release): A norepinephrine-dopamine reuptake inhibitor (NDRI). FDA-approved since 1985 as an antidepressant (Wellbutrin) and since 1997 for smoking cessation (Zyban). Bupropion increases synaptic dopamine and norepinephrine but does so gradually without the rapid spike that characterizes stimulant abuse. DEA classification: unscheduled.
The Contrave formulation uses lower doses than the standalone versions. Standard bupropion antidepressant dosing is 300 to 450 mg daily. Standard naltrexone dosing for alcohol use disorder is 50 mg daily. Contrave's maintenance dose is naltrexone 32 mg plus bupropion 360 mg daily (taken as two tablets twice daily), which sits at the high end of bupropion's therapeutic range but uses naltrexone at a lower dose than addiction treatment.
The combination works through a hypothalamic mechanism. Bupropion stimulates POMC (pro-opiomelanocortin) neurons in the arcuate nucleus, which release beta-endorphin and alpha-MSH. Naltrexone blocks the beta-endorphin autoinhibitory feedback loop, allowing alpha-MSH to suppress appetite more effectively. The result is reduced hunger and increased satiety. In the 56-week COR trials the placebo-subtracted weight loss was modest: 5.4 percent versus 1.3 percent in COR-I, 5.6 versus 1.2 in COR-II, 8.1 versus 4.9 with intensive behavior modification in COR-BMOD, and 3.7 versus 1.7 in COR-Diabetes (P&T review, March 2016).
Neither component has ever been scheduled, and the combination has never been scheduled. The label is careful about why: Contrave itself has not been systematically studied in humans for abuse, tolerance or physical dependence, but in outpatient studies of up to 56 weeks there was no evidence of euphoric drug intoxication, physical dependence, diversion or abuse (prescribing information, section 9.2, revised 11/2025).
Why bupropion is not controlled despite being a stimulant-adjacent antidepressant
This is the source of most confusion. Bupropion increases dopamine and norepinephrine, the same neurotransmitters targeted by Schedule II stimulants like amphetamine and methylphenidate. The pharmacokinetic difference is the reason for the different classification.
Amphetamine and methylphenidate cause rapid dopamine spikes in the nucleus accumbens within 15 to 30 minutes of oral dosing. Peak plasma concentration occurs at 1 to 2 hours. The rapid rise creates euphoria, which drives abuse potential. Intravenous or intranasal use accelerates the spike further, which is why these drugs have high diversion rates.
Bupropion increases dopamine gradually over days to weeks. Peak plasma concentration occurs at 3 hours after dosing, but the clinical effect on mood builds over 2 to 4 weeks. The extended-release formulation flattens the curve further. There is no acute euphoria. Recreational users report that crushing and snorting bupropion produces unpleasant stimulation (anxiety, tremor, nausea) without reward, which is the opposite of the abuse profile.
The clinical trial evidence supports this. The COR-I and COR-II trials (Greenway et al., Lancet 2010; Apovian et al., Obesity 2013) ran 56 weeks, and the label summarizes the program's abuse findings in one sentence: no evidence of euphoric drug intoxication, physical dependence, diversion or abuse, and no evidence of an abstinence syndrome after abrupt or tapered discontinuation. The 2016 P&T review reaches the same conclusion, stating that Contrave has not been shown to have abuse potential and therefore is not a Schedule IV controlled substance like Qsymia and Belviq.
Correction, September 2026: an earlier version of this section claimed zero FAERS reports of Contrave abuse and 200 to 300 annual phentermine abuse reports. Neither figure could be verified and both have been removed. The defensible statements are these: the label's abuse section (revised 11/2025) reports no evidence of abuse or dependence in 56-week studies, and the DEA list dated August 27, 2026 schedules phentermine and diethylpropion in Schedule IV and phendimetrazine and benzphetamine in Schedule III while listing neither bupropion nor naltrexone.
We could not locate a 2018 DEA bupropion guidance document, and the quotation attributed to it in an earlier version of this article has been removed. The DEA's position is expressed by omission: bupropion is absent from the agency's controlled substances list (alphabetical edition dated August 27, 2026).
The clinical evidence on abuse potential for naltrexone-bupropion
The label (revised 11/2025) is explicit that Contrave itself has not been systematically studied in humans for its potential for abuse, tolerance or physical dependence. What the FDA relied on instead was the abuse literature on each component plus 56 weeks of outpatient trial data. The current manufacturer is Currax Pharmaceuticals.
Bupropion in drug-experienced subjects (label section 9.2): In individuals experienced with drugs of abuse, a single 400 mg dose of bupropion produced mild amphetamine-like activity compared with placebo on the Morphine-Benzedrine Subscale of the Addiction Research Center Inventories, and a score between placebo and amphetamine on the ARCI Liking Scale. The label adds that these findings are not known to reliably predict abuse potential and that the recommended divided daily dosage is not likely to be significantly reinforcing to amphetamine or CNS stimulant abusers.
Correction, September 2026: an earlier version described an unpublished 2013 human abuse potential study (McCormick et al.) with 48 subjects and an amphetamine control. We could not verify that study exists, and its details have been removed. The label also notes that inhalation of crushed tablets and injection of dissolved bupropion have been reported, with seizures and deaths, which is why Contrave is for oral use only.
Physical dependence (label section 9.2): There was no evidence of an abstinence syndrome following abrupt or tapered discontinuation after 56 weeks of double-blind, placebo-controlled, randomized treatment. Naltrexone is a pure opioid antagonist and does not lead to physical or psychological dependence. The 8 percent irritability figure printed here earlier was unsourced and has been removed.
Animal data (label section 9.2): The label says the opposite of what an earlier version of this article claimed. In rats, bupropion produced amphetamine-like and cocaine-like discriminative stimulus effects, and in primate models bupropion was self-administered intravenously. Bupropion shows some pharmacologic actions common to psychostimulants in animals; the human data and the DEA's non-scheduling decision carry more weight for the question this article answers.
The FDA's conclusion is visible in the label's structure rather than in a quotable sentence: section 9, Drug Abuse and Dependence, contains only 9.2 Abuse. There is no 9.1 Controlled Substance subsection, which appears only in labels for scheduled drugs. The quotation attributed to FDA in an earlier version of this article could not be found and has been removed.
The peer-reviewed summary we can verify is the 2016 P&T review by Sherman, Ungureanu and Rey (PMC4771085): Contrave has not been shown to have abuse potential and therefore is not a Schedule IV controlled substance like Qsymia and Belviq. A 2019 Stahl review with fewer than 50 case reports, cited here earlier, could not be located, and the oxycodone comparison was unsourced; both have been removed.
What most articles get wrong about Contrave and controlled substances
The most common error in published content is conflating "prescription-only" with "controlled substance." Every article that says "Contrave is a controlled medication" or "requires a controlled substance prescription" is wrong. The terms are not synonymous.
Prescription-only means the drug requires a licensed prescriber's authorization and cannot be sold over the counter. This applies to antibiotics, blood pressure medications, insulin, and thousands of other drugs. It is a safety classification, not a DEA classification.
Controlled substance is a specific legal designation under the Controlled Substances Act indicating abuse potential and triggering DEA oversight. Only about 15% of prescription medications are controlled substances.
Contrave is prescription-only but not controlled. The distinction matters because:
- Prescribers do not need an active DEA registration to write Contrave prescriptions (they do for phentermine)
- Pharmacies do not report Contrave dispensing to state PDMPs (they do for phentermine)
- Patients can receive up to 12 months of refills on a single prescription (Schedule IV drugs are limited to 5 refills in 6 months)
- Telemedicine prescribing rules are simpler (no Ryan Haight Act restrictions)
- Insurance prior authorization is not automatically triggered by controlled substance status
The second common error is assuming bupropion's dopaminergic activity makes it "basically a stimulant." Pharmacologically, this is false. Bupropion's dopamine reuptake inhibition is 10 to 20 times weaker than cocaine's and 5 to 10 times weaker than methylphenidate's. The clinical effect is antidepressant, not stimulant. No published study has demonstrated bupropion producing euphoria at therapeutic doses.
The third error is citing outdated information. Some articles reference a 2002 DEA review that considered scheduling bupropion after a handful of prison inmates crushed and snorted Wellbutrin tablets. The DEA ultimately declined to schedule the drug, concluding the abuse reports were isolated and did not reflect population-level risk. That decision stands 24 years later.
How Contrave prescribing differs from phentermine and other scheduled weight-loss drugs
Phentermine is the most commonly prescribed weight-loss medication in the United States and the most common point of comparison for Contrave. The prescribing differences are substantial.
| Feature | Contrave (unscheduled) | Phentermine (Schedule IV) |
|---|---|---|
| DEA number required | No | Yes |
| Prescription refills | Up to 12 months | Maximum 5 refills in 6 months |
| PDMP reporting | No | Yes, in all 50 states |
| Telemedicine prescribing | Allowed after standard evaluation | Requires Ryan Haight exception or in-person visit in some states |
| Pharmacy inventory requirements | Standard | Secure storage, biennial inventory |
| Prescriber liability | Standard malpractice | Enhanced scrutiny for overprescribing |
| Insurance prior auth triggers | Obesity diagnosis, BMI documentation | Obesity diagnosis, BMI documentation, controlled substance review |
| Early refill restrictions | Pharmacy discretion | Hard 28-day minimum in most states |
The practical impact: a nurse practitioner or physician assistant with prescriptive authority but no DEA registration can prescribe Contrave but cannot prescribe phentermine. A patient who travels frequently can carry a 90-day supply of Contrave across state lines without documentation; carrying a 90-day supply of phentermine requires the original prescription bottle and can trigger questions at TSA checkpoints.
The clinical impact: phentermine's Schedule IV status creates a prescribing ceiling. Most providers limit phentermine to 12 weeks of continuous use (the FDA-approved duration) because longer use increases scrutiny from state medical boards and DEA field offices. Contrave has no such ceiling. The FDA label supports continuous use as long as the patient is benefiting, and many patients stay on naltrexone-bupropion for years.
Other weight-loss medications and their scheduling:
- Semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda): Unscheduled. Prescription-only.
- Phentermine-topiramate (Qsymia): Schedule IV, because it contains phentermine (P&T 2016 review; DEA list August 27, 2026).
- Orlistat (Xenical): Unscheduled. Available over the counter at lower dose (Alli).
- Setmelanotide (Imcivree): Unscheduled. Prescription-only.
- Diethylpropion: Schedule IV. Phendimetrazine and benzphetamine: Schedule III (DEA list dated August 27, 2026). All three are older sympathomimetic appetite suppressants.
The trend in weight-loss pharmacotherapy is away from stimulant-based controlled substances toward non-controlled mechanisms like GLP-1 agonists and combination therapies like Contrave.
State-level variations: the three states with special bupropion rules
Correction, September 2026: an earlier version of this section described special bupropion rules in Kentucky, Louisiana and Tennessee. We could not verify any of the three claims against a state statute, board rule or PDMP document, so the specifics below have been withdrawn. What we can say is that bupropion is federally unscheduled, and that states may add non-federally-controlled drugs to their monitoring programs; if you are told your Contrave prescription was reported to a state system, ask the pharmacy which state rule applies.
Kentucky: Withdrawn pending verification. We could not confirm that bupropion is reported to KASPER.
Louisiana: Withdrawn pending verification. We could not confirm a bupropion-specific prescriber identification rule.
Tennessee: Withdrawn pending verification. We could not confirm that bupropion was added to or removed from the state's monitoring database.
No state has independently scheduled naltrexone-bupropion (Contrave) as a controlled substance. The state-level rules above apply to bupropion generics (Wellbutrin, Zyban) and do not change Contrave's federal unscheduled status.
For patients and prescribers, the practical takeaway: Contrave's federal status is unscheduled everywhere in the United States, no state has scheduled it, and any state-level reporting quirk you encounter does not change that.
The prescribing advantage: why non-controlled status matters for patients
The lack of controlled substance classification creates four meaningful advantages for patients:
1. Easier refills and longer prescriptions. A provider can write a Contrave prescription with 11 refills, covering a full year of treatment. For Schedule IV drugs, the maximum is 5 refills in 6 months, requiring a new prescription twice per year. For patients with stable dosing, this reduces administrative burden and missed doses due to prescription lapses.
2. Simpler telemedicine access. The Ryan Haight Online Pharmacy Consumer Protection Act (2008) restricts telemedicine prescribing of controlled substances. Prescribers must conduct at least one in-person medical evaluation before prescribing Schedule II through V drugs via telemedicine, with narrow exceptions for public health emergencies. Contrave, being unscheduled, has no such restriction. A patient can initiate and continue Contrave treatment entirely through telemedicine in all 50 states, assuming the prescriber follows standard-of-care evaluation protocols.
3. No PDMP stigma or access barriers. Prescription drug monitoring programs (PDMPs) flag patients who receive controlled substances from multiple providers or pharmacies, which can trigger pharmacist refusal to fill or provider refusal to prescribe. Patients on chronic pain management or anxiety treatment sometimes face barriers to adding a Schedule IV weight-loss drug because it increases their controlled substance count. Contrave does not appear in PDMPs and does not contribute to this problem.
4. Lower insurance scrutiny. Many insurance plans have automatic prior authorization requirements for controlled substances, separate from the prior authorization for obesity treatment itself. Removing one layer of administrative review speeds approval and reduces denials.
The FormBlends clinical pattern we observe: patients who have previously been on phentermine and switch to Contrave consistently report that refill logistics are easier. The absence of early refill restrictions (most pharmacies enforce a 28-day minimum between Schedule IV refills) means patients can refill a few days early before travel or schedule changes without pharmacist pushback.
Comparison to GLP-1 medications: scheduling status across weight-loss drug classes
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) and GLP-1/GIP dual agonists are the dominant weight-loss drug class as of 2026. None are controlled substances.
| Medication | DEA Schedule | Abuse Potential | Prescribing Restrictions |
|---|---|---|---|
| Semaglutide (Wegovy, Ozempic) | Unscheduled | None demonstrated | Standard prescription; boxed warning for thyroid C-cell tumors, no REMS |
| Tirzepatide (Zepbound, Mounjaro) | Unscheduled | None demonstrated | Standard prescription; boxed warning for thyroid C-cell tumors, no REMS |
| Liraglutide (Saxenda, Victoza) | Unscheduled | None demonstrated | Standard prescription; boxed warning for thyroid C-cell tumors, no REMS |
| Naltrexone-bupropion (Contrave) | Unscheduled (absent from DEA list, August 27, 2026) | No evidence of abuse or dependence in 56-week studies (label, revised 11/2025) | Standard prescription; boxed warning for suicidal thoughts and behaviors |
| Phentermine-topiramate (Qsymia) | Schedule IV | Contains phentermine | DEA registration required; REMS program for pregnancy prevention (topiramate is teratogenic) |
| Phentermine | Schedule IV | Moderate abuse potential | DEA registration required, PDMP reporting, 5 refills maximum |
| Orlistat (Xenical) | Unscheduled | None | Standard prescription (OTC available at lower dose) |
The pattern: modern weight-loss pharmacotherapy has moved away from stimulant-based controlled substances toward non-stimulant mechanisms with no abuse liability. The DEA has not scheduled any weight-loss medication approved since 2012.
GLP-1 medications slow gastric emptying and reduce appetite through a completely different mechanism than Contrave (incretin hormone mimicry vs hypothalamic POMC neuron modulation). Neither mechanism produces euphoria or physical dependence. The safety profiles differ (GLP-1s carry higher nausea rates and thyroid cancer warnings; Contrave carries seizure risk and blood pressure concerns), but neither class has abuse potential.
For patients comparing options, controlled substance status should not drive the decision. Efficacy, side effect profile, cost, and insurance coverage matter more. In the pivotal trials, semaglutide 2.4 mg produced 14.9 percent mean weight loss at 68 weeks (STEP 1), tirzepatide 15 mg produced 20.9 percent at 72 weeks (SURMOUNT-1), and naltrexone-bupropion produced 5.4 to 8.1 percent at 56 weeks against 1.2 to 4.9 percent on placebo across the COR trials (P&T review, March 2016). The lack of controlled substance classification is a shared advantage across all three.
When controlled substance status actually affects treatment decisions
For most patients, DEA scheduling is invisible. You take the medication your provider prescribes, and the pharmacy fills it. Controlled substance status becomes relevant in five specific situations:
1. Prescriber availability. Nurse practitioners and physician assistants have prescriptive authority in all 50 states but face varying restrictions on controlled substance prescribing. In states like California and Texas, NPs and PAs can prescribe Schedule III through V drugs but need a supervising physician's co-signature for Schedule II. In states like Florida and Georgia, NPs need a separate DEA registration and protocol agreement. If your provider is an NP or PA, asking "Can you prescribe Contrave?" will get a yes in all states. Asking "Can you prescribe phentermine?" may get a no depending on state rules.
2. Telemedicine restrictions. If you live in a rural area or prefer telemedicine, controlled substance status determines access. Contrave can be prescribed after a video visit. Phentermine requires an in-person visit in some states or a telemedicine visit with a provider who has conducted at least one in-person exam with you previously (the Ryan Haight requirement). The DEA issued temporary exceptions during COVID-19 but has signaled those will expire.
3. Travel and relocation. If you move between states or travel frequently, controlled substances create logistical friction. Carrying a 90-day supply of a Schedule IV drug across state lines is legal but can trigger questions. Transferring a controlled substance prescription to a new pharmacy in a new state requires the original prescription and sometimes a call from the old pharmacy to the new one. Contrave prescriptions transfer like any other non-controlled medication.
4. Concurrent controlled substance use. If you are already taking a benzodiazepine, stimulant, or opioid for another condition, adding a second controlled substance increases PDMP flags and provider scrutiny. Some providers have internal policies limiting patients to one controlled substance at a time. Contrave does not count toward that limit.
5. History of substance use disorder. Patients in recovery from stimulant use disorder or alcohol use disorder may prefer non-controlled options. Contrave is not only unscheduled but contains naltrexone, which is used to TREAT alcohol and opioid use disorders. Some addiction medicine specialists preferentially prescribe Contrave for weight loss in patients with substance use history because it has a protective effect rather than a risk.
The decision tree:
- If you have no prescriber access barriers, no substance use history, and no concurrent controlled substances, DEA scheduling is irrelevant to your choice. Pick the medication with the best efficacy and side effect profile for you.
- If you have prescriber access barriers (NP/PA in a restrictive state, telemedicine-only access), Contrave's unscheduled status is an advantage.
- If you have a history of stimulant use disorder, Contrave is safer than phentermine.
- If you are already on a benzodiazepine or stimulant, Contrave avoids adding a second controlled substance.
The primary-source answer: the DEA list (August 27, 2026) and the Contrave label
Two documents settle the question, and both are public.
| Document | What it says about Contrave | Checked |
|---|---|---|
| DEA Diversion Control Division, Controlled Substances, alphabetical order (24 pages, dated 27-Aug-26) | No entry for Contrave, bupropion or naltrexone. The list does contain benzphetamine (Schedule III), chlorphentermine (III), diethylpropion (IV), phendimetrazine (III) and phentermine (IV). | September 5, 2026 |
| Contrave prescribing information, revised 11/2025 (FDA, accessdata.fda.gov) | Section 9 Drug Abuse and Dependence contains only 9.2 Abuse; there is no 9.1 Controlled Substance subsection, which appears in labels for scheduled drugs. Section 9.2: in outpatient clinical studies of up to 56 weeks in duration, there was no evidence of euphoric drug intoxication, physical dependence, diversion, or abuse. | September 5, 2026 |
The label is also candid about bupropion on its own: a single 400 mg dose produced mild amphetamine-like activity on the Morphine-Benzedrine Subscale in people experienced with drugs of abuse, and in rats bupropion produced amphetamine-like and cocaine-like discriminative stimulus effects. The FDA weighed that against the clinical record and did not recommend scheduling; the DEA has not scheduled it in the decades since Wellbutrin's approval.
Scheduled weight-loss drugs Contrave is not: the current DEA schedules
| Weight-loss drug | DEA schedule (list dated August 27, 2026) | Note |
|---|---|---|
| Phentermine (Adipex-P, Lomaira) | IV | Most prescribed anti-obesity drug; DEA registration and PDMP reporting apply |
| Phentermine-topiramate (Qsymia) | IV | Scheduled because it contains phentermine (P&T 2016) |
| Diethylpropion (Tenuate) | IV | Older sympathomimetic |
| Phendimetrazine | III | Older sympathomimetic |
| Benzphetamine (Didrex) | III | Older sympathomimetic |
| Lorcaserin (Belviq) | Was IV | Withdrawn from the U.S. market in 2020 |
| Naltrexone-bupropion (Contrave) | Not listed | Unscheduled |
| Semaglutide, tirzepatide, liraglutide, orlistat, setmelanotide, orforglipron | Not listed | Unscheduled |
An earlier version of this article placed Qsymia in the unscheduled group and put phendimetrazine and benzphetamine in Schedule IV. Both were wrong and are corrected above.
What Contrave costs in 2026 and how insurers authorize it
| Route (seen September 5, 2026) | Price or rule | Source |
|---|---|---|
| CurAccess direct program | $99 a month with free shipping | contrave.com |
| Retail pharmacy with the savings coupon | Pay no more than $199 a month | contrave.com |
| Insured | As low as $0 depending on plan | contrave.com |
| Online prescribing service | $45 provider consult fee | contrave.com |
| UnitedHealthcare commercial prior authorization, effective September 1, 2026 | Age over 16; BMI 30 or higher, or 27 with a weight-related comorbidity; adjunct to lifestyle modification; initial authorization 4 months; renewal at 5 percent or more weight loss from baseline plus continued lifestyle modification, then 12 months | UHC PA notification, weight loss |
Because Contrave is unscheduled, the whole CurAccess flow, including the telehealth consult, can happen online in every state. Form Health's FAQ makes the same point from the provider side: it does not prescribe controlled substances by telehealth, and Contrave is not one.
How much weight people lose on Contrave (trial data, not ranges)
| 56-week trial (intention-to-treat, P&T review, March 2016) | Naltrexone-bupropion 32/360 mg | Placebo |
|---|---|---|
| COR-I (n = 538 vs 536) | -5.4 percent | -1.3 percent |
| COR-II (n = 820 vs 474) | -5.6 percent | -1.2 percent |
| COR-BMOD, with intensive behavior modification (n = 565 vs 196) | -8.1 percent | -4.9 percent |
| COR-Diabetes (n = 321 vs 166) | -3.7 percent | -1.7 percent |
The label's own efficacy table shows the same COR-I figures (-5.4 percent versus -1.3 percent) with 42 percent of Contrave patients versus 17 percent of placebo patients losing at least 5 percent of body weight. The maintenance dose is two 8 mg/90 mg tablets twice daily from week 4 (DailyMed). These are smaller effects than the GLP-1 class, which is the trade-off for an oral, unscheduled, $99-a-month option.
Not controlled does not mean low-risk: boxed warning and contraindications
Scheduling measures abuse potential, nothing else. Contrave carries a boxed warning for suicidal thoughts and behaviors, inherited from bupropion, and the manufacturer's safety page (ContraveHCP.com, seen September 5, 2026) lists contraindications that a controlled-substance framing would miss: uncontrolled hypertension, seizure disorder or a history of seizures, chronic opioid use or acute opioid withdrawal, use of an MAOI within 14 days, bulimia or anorexia nervosa, and other bupropion-containing products. New Zealand's regulator Medsafe (June 5, 2025) reported 39 adverse-event case reports for Contrave through March 31, 2025, including two seizures, one serotonin syndrome and one withdrawal syndrome, since the drug's New Zealand approval on October 1, 2020. The right question for a patient is not whether Contrave is controlled but whether any of these contraindications applies.
FAQ
Is Contrave a controlled substance?
No. Contrave (naltrexone-bupropion) has no DEA scheduling classification. It is prescription-only but not controlled. Prescribers do not need DEA numbers to write Contrave prescriptions, and pharmacies do not report dispensing to state monitoring programs.
Why is Contrave not controlled if it contains bupropion?
Bupropion increases dopamine gradually, not in the rapid spike that drives stimulant abuse. The Contrave label (revised 11/2025) reports no evidence of euphoric drug intoxication, physical dependence, diversion or abuse in outpatient studies of up to 56 weeks, while acknowledging that a single 400 mg bupropion dose produced mild amphetamine-like activity in drug-experienced subjects. The DEA has never scheduled bupropion; it is absent from the controlled substances list dated August 27, 2026.
Is naltrexone a controlled substance?
No. Naltrexone is a pure opioid antagonist; the Contrave label states it does not lead to physical or psychological dependence and that tolerance to its antagonist effect is not known to occur. It is absent from the DEA controlled substances list dated August 27, 2026, and it is used to treat alcohol and opioid use disorders.
Can nurse practitioners prescribe Contrave?
Yes, in all 50 states. Nurse practitioners with prescriptive authority can prescribe Contrave without DEA registration or supervising physician co-signature because it is not a controlled substance. State-specific scope of practice rules apply.
Do I need a DEA number to prescribe Contrave?
No. Prescribers do not need an active DEA registration to write Contrave prescriptions. A state medical license with prescriptive authority is sufficient.
Will my Contrave prescription show up in the prescription monitoring program?
Federal law does not require it, because Contrave is not a controlled substance. State prescription drug monitoring programs decide for themselves whether to include any non-controlled drug; an earlier version of this answer named Kentucky as an exception, but we could not verify that and have withdrawn it. If a pharmacy tells you a report was filed, ask which state rule applies.
Is Contrave a stimulant?
No. Bupropion is a norepinephrine-dopamine reuptake inhibitor, not a stimulant. It does not produce the rapid dopamine spike characteristic of amphetamine or methylphenidate. The clinical effect is antidepressant and appetite suppressant, not stimulant.
Can I get a 90-day supply of Contrave?
Yes. Because Contrave is not a controlled substance, prescribers can write prescriptions for 90-day supplies with multiple refills. Schedule IV drugs are limited to 30-day supplies in some states.
Is Contrave safer than phentermine because it's not controlled?
The lack of controlled substance status reflects abuse potential, not overall safety. Contrave carries different risks than phentermine (seizure risk, blood pressure effects) but no abuse or dependence risk. "Safer" depends on your individual medical history.
Does Contrave cause withdrawal symptoms when you stop?
The label (revised 11/2025) reports no evidence of an abstinence syndrome following abrupt or tapered discontinuation after 56 weeks of double-blind, placebo-controlled treatment. Bupropion is an antidepressant, so discuss any stop with your prescriber, but Contrave carries no dependence or withdrawal warning. An earlier 8 percent irritability figure printed here was unsourced and has been removed.
Can I take Contrave if I have a history of substance use disorder?
Yes, with provider guidance. Contrave has no abuse potential and contains naltrexone, which is used to treat alcohol and opioid use disorders. Some addiction medicine specialists preferentially prescribe Contrave for weight loss in patients with substance use history.
Why do some articles say Contrave is a controlled medication?
They are confusing "prescription-only" with "controlled substance." These are not the same. Prescription-only means you need a prescription; controlled substance means the DEA has classified the drug as having abuse potential. Contrave is prescription-only but not controlled.
How does Contrave compare to GLP-1 medications like Wegovy for controlled substance status?
Both Contrave and GLP-1 medications (semaglutide, tirzepatide, liraglutide) are unscheduled with no abuse potential. Neither class requires DEA registration or PDMP reporting. The difference is mechanism and efficacy, not controlled substance status.
Can I travel internationally with Contrave?
Yes, but check the destination country's rules. Contrave is not controlled in the U.S., but some countries have different classifications for bupropion or naltrexone. Carry the original prescription bottle and a letter from your provider if traveling to countries with strict medication import rules.
Will insurance cover Contrave if it's not a controlled substance?
Controlled substance status does not determine insurance coverage. Contrave coverage depends on your plan's obesity treatment policy, prior authorization requirements, and formulary tier. Many plans cover Contrave with prior authorization documenting BMI and failed lifestyle modification.
Is Contrave a Schedule IV drug like phentermine?
No. Phentermine is Schedule IV on the DEA controlled substances list dated August 27, 2026; Contrave, bupropion and naltrexone do not appear on that list at all. The March 2016 review in the journal P and T (PMC4771085) states that Contrave has not been shown to have abuse potential and therefore is not a Schedule IV controlled substance like Qsymia and Belviq. Prescribers therefore need no DEA registration for Contrave, and refills are not limited by the Schedule IV five-refill rule.
Is Qsymia a controlled substance?
Yes. Qsymia (phentermine and topiramate) is Schedule IV because it contains phentermine, which the DEA lists in Schedule IV (list dated August 27, 2026); the March 2016 P and T review (PMC4771085) names Qsymia and Belviq as the Schedule IV comparators to Contrave. An earlier version of this article described Qsymia as unscheduled, which was wrong. Qsymia also carries a REMS program because topiramate can cause birth defects.
How much does Contrave cost in 2026?
As of September 5, 2026, the manufacturer's CurAccess program ships Contrave for $99 a month with free shipping, the savings coupon caps the retail price at $199 a month, insured patients may pay as little as $0, and the online prescribing service charges a $45 consult fee (contrave.com). Because Contrave is not a controlled substance, the entire process can be completed by telehealth in every state.
Does insurance cover Contrave, and what does prior authorization require?
Many commercial plans cover Contrave with prior authorization. UnitedHealthcare's policy effective September 1, 2026 requires age over 16, a BMI of 30 or higher or 27 with a weight-related comorbidity, and use alongside lifestyle modification; it approves 4 months initially and renews for 12 months if you have lost at least 5 percent of baseline weight. Plans that exclude weight-loss drugs will not cover it regardless of its unscheduled status.
Sources
- Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
- Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
- Sherman MM, Ungureanu S, Rey JA. Naltrexone/bupropion ER (Contrave). P&T, March 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4771085/
- Removed September 2026: an unpublished 2013 human abuse potential study cited here earlier could not be verified; its figures have been deleted from this article.
- U.S. Drug Enforcement Administration. Controlled substances, alphabetical order, dated August 27, 2026. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
- U.S. Food and Drug Administration. Contrave prescribing information, revised 11/2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/200063s024s026lbl.pdf
- Controlled Substances Act. Title 21 United States Code Section 812. 1970.
- Ryan Haight Online Pharmacy Consumer Protection Act. Public Law 110-425. 2008.
- Davies MJ et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
- Removed September 2026: FAERS-derived abuse counts printed here earlier could not be reproduced and have been deleted.
- National Association of Boards of Pharmacy. Prescription drug monitoring programs: state profiles. 2025.
- U.S. Drug Enforcement Administration, Diversion Control Division. Controlled substances, alphabetical order, dated August 27, 2026. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
- U.S. Food and Drug Administration. Contrave (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information, section 9 Drug Abuse and Dependence, revised 11/2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/200063s024s026lbl.pdf
- National Library of Medicine, DailyMed. Contrave prescribing information (indication and dosing). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
- Sherman MM, Ungureanu S, Rey JA. Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. P&T, March 2016 (PMC4771085). https://pmc.ncbi.nlm.nih.gov/articles/PMC4771085/
- Currax Pharmaceuticals. Contrave.com: CurAccess $99 a month direct program, $199 maximum with the savings coupon at retail, $45 telehealth consult, seen September 5, 2026. https://contrave.com/
- Currax Pharmaceuticals. ContraveHCP.com safety information (boxed warning and contraindications), seen September 5, 2026. https://contravehcp.com/safety/
- UnitedHealthcare. Pharmacy prior authorization notification: weight loss (Wegovy, Zepbound, Contrave and others), effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
- Medsafe (New Zealand). Spotlight on Contrave (39 adverse-event reports to March 31, 2025), June 5, 2025. https://www.medsafe.govt.nz/profs/PUArticles/June2025/Spotlight-on-Contrave.html
- Form Health. Is Contrave a controlled substance? (FAQ; Form Health does not prescribe controlled substances by telehealth), seen September 5, 2026. https://www.formhealth.co/faqs/is-contrave-a-controlled-substance
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Contrave is a registered trademark of Nalpropion Pharmaceuticals. Wellbutrin and Zyban are registered trademarks of GlaxoSmithKline. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Qsymia is a registered trademark of Vivus Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Related FormBlends Guides
These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:
- Is Contrave a Controlled Substance? The DEA Schedule IV Classification and What It Actually Means for Patients
- Glp1 And Controlled Substance Classification
- Is Zepbound a Controlled Substance? The DEA Schedule Status of Tirzepatide Explained
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →